Back to search

University of Alabama Birmingham

Examination Of Novel Statistical Designs For Phase II And Phase III Clinical Trials

Abstract

dc:description.abstract

Clinical trials to determine the usefulness of a new treatment are usually conducted in four (4) phases. Each phase is designed to answer a distinct research question about the usefulness of the new treatment. Phase I trials determine the safe dose range of the new treatment identify the possible side effects and other treatment associated toxicity issues, in a small group of healthy people. In phase II trials, the efficacy and safety of the new treatment is investigated in a larger group of individuals usually from the diseased population of interest. Phase III trials, conducted in large groups of people, further investigate the effectiveness of the new treatment, monitor its side effects, compare it to an established form of treatment for the disease and collect information that help determine the safe use of the new treatment. Phase IV trials, also called post marketing surveillance studies, are conducted after the treatment has been marketed to gather more information on the side effects in various subgroups and any side effects associated with long-term use. Several statistical designs have been proposed to answer the research questions posed at each phase. In the first paper of this dissertation, we propose a method for designing phase II trials that allows for early termination of the trial for lack of efficacy. The second paper, proposes a two-stage adaptive procedure for a phase III trial when there is statistical evidence that the effect of the treatment might differ depending on the characteristics of the individuals being investigated. The third paper, presents a iii modification of the two-stage adaptive procedure proposed in paper 2. The modified procedure allows for early termination of any stratum of the trial that shows little evidence of the treatment efficacy at the beginning of the second stage. A conditional power approach is implemented in all three designs to: 1) terminate early a trial or an arm of the trial due to lack of evidence of efficacy in papers 1 and 3 respectively; 2) control the type I error rate at the end of stage 2 conditioned on a statistically significant covariate by treatment interaction for the procedures proposed in papers 2 and 3.

Degree

thesis:*
Level thesis:degree_level
Dissertation

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Ayanlowo, Ayanbola Olajumoke
Contributors dc:contributor
  • David T Redden
  • Christopher Coffey
  • Gary Cutter
  • Charles Katholi
  • David Kimberlin
  • Sharina Person

Subjects

dc:subject × 1

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
University of Alabama Birmingham
Base URL
digitalcommons.library.uab.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Ayanlowo, Ayanbola Olajumoke. Examination Of Novel Statistical Designs For Phase II And Phase III Clinical Trials. Dissertation thesis, https://digitalcommons.library.uab.edu/etd-collection/3660